


**F.No. 12-01/2014-DC (Pt-20)**  
**Directorate General of Health Services**  
**Office of Drugs Controller General (India)**

FDA Bhawan,  
Kotla Road, New Delhi  
Dated: 15-06-2016

**Notice**

Meeting of Subject Expert Committee constituted by the Ministry of Health and Family Welfare to advise DCG(I) in matters related to approval of New Drugs, Subsequent New Drug, Fixed Dose Combinations, Global Clinical Trials, Biological & Medical Devices are being conducted in O/o DCG(I) to review the above applications by the experts. The applicant firms are also called to present their case before Subject Expert Committee during the meeting.

It has been observed that some of the applicant firm are not attending the scheduled meeting of Subject Expert Committee. This matter has been viewed seriously. All the applicant firms are here by advised that once their applications are included in the Agenda of the SEC, their presence in the meeting is mandatory, failing which their applications will be treated as withdrawn and the matter will be treated as closed. Inclusion of their applications in subsequent SEC meetings shall be considered after they turning written justification for their absence and shall be at the sole discretion of the DCG(I)

  
(Dr. G N. Singh)  
Drugs Controller General (India)

Copt to

1. All Pharmaceuticals Associations
2. All JDC(I)s/DDC(I)s/ADC(I)s/ of CDSCO(HQ)